Risk-Based Contamination Limits Suggested For Highly Potent Drugs
Executive Summary
As more highly potent and highly toxic drugs are being developed, regulators are looking into risks posed by contamination of non-contact surfaces, yet until recently, there was scant guidance on how to assess these risks.
You may also be interested in...
Refurbished EU GMP guideline for drugs effective March 2015
The European Commission has made a raft of revisions to its good manufacturing practice (GMP) guideline that deals with basic requirements for medicinal products.
EMA consults on tackling cross-contamination at shared drug manufacturing facilities
The European Medicines Agency is inviting feedback on a draft guideline that explains how companies that make different medicinal products at shared manufacturing facilities should review and evaluate pharmacological and toxicological data of individual products to tackle cross-contamination issues1.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”